GlucoTrack
Open
$0.82
Prev. Close
$0.82
High
$0.83
Low
$0.82
Market Snapshot
$838.47K
-0.0
-4018.00
11
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
emptyResult
GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company is headquartered in Rutherford, New Jersey and currently employs 11 full-time employees. The company went IPO on 2013-04-09. The firm is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. The company has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The firm has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Recently from Cashu
GlucoTrack's Strategic Steps Towards FDA Approval for Innovative Diabetes Monitoring Device
GlucoTrack's Path to FDA Approval: A Strategic Development in Diabetes Management GlucoTrack, a pioneering company in the diabetes management arena, makes a significant announcement regarding its regu…
Title: GlucoTrack Stock Update: Key Insights and Market Trends
Please provide the text that you would like me to summarize into a 300 to 500-word article.
GlucoTrack Stock Update: Recent Developments and Future Prospects
Please provide the text that you would like me to summarize into an article.
GlucoTrack: Seeking Clarification on Content for Summary and Article Development
I'm sorry, but it seems there was a misunderstanding, as I don't have any specific content to summarize. If you provide the text or details about GlucoTrack or relevant developments in the industry, I…